These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 18362222)

  • 1. Higher detection rate of JAK2 mutation using plasma.
    Ma W; Kantarjian H; Zhang X; Sun W; Buller AM; Jilani I; Schwartz JG; Giles F; Albitar M
    Blood; 2008 Apr; 111(7):3906-7. PubMed ID: 18362222
    [No Abstract]   [Full Text] [Related]  

  • 2. Plasma quantitation of JAK2 mutation is not suitable as a clinical test: an artifact of storage.
    Salama ME; Swierczek SI; Hickman K; Wilson A; Prchal JT
    Blood; 2009 Jul; 114(1):223-4; author reply 224. PubMed ID: 19574481
    [No Abstract]   [Full Text] [Related]  

  • 3. Detection of the JAK2 mutation in myeloproliferative neoplasms by asymmetric PCR with unlabeled probe and high-resolution melt analysis.
    Cao HC; Lin J; Qian J; Yao DM; Li Y; Yang J; Chen Q; Chai HY; Xiao GF
    J Clin Lab Anal; 2011; 25(4):300-4. PubMed ID: 21786333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of whole blood vs purified blood granulocytes for the detection and quantitation of JAK2(V617F).
    Hermouet S; Dobo I; Lippert E; Boursier MC; Ergand L; Perrault-Hu F; Pineau D
    Leukemia; 2007 May; 21(5):1128-30. PubMed ID: 17301814
    [No Abstract]   [Full Text] [Related]  

  • 5. Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias.
    Ma W; Kantarjian H; Zhang X; Yeh CH; Zhang ZJ; Verstovsek S; Albitar M
    J Mol Diagn; 2009 Jan; 11(1):49-53. PubMed ID: 19074595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma levels of JAK2 mRNA in patients with chronic myeloproliferative diseases with and without V617F mutation: implications for prognosis and disease biology.
    Ma W; Kantarjian H; Zhang X; Yeh CH; Zhang ZJ; Verstovsek S; O'Brien S; Giles F; Albitar M
    Int J Lab Hematol; 2010 Feb; 32(1 Pt 2):95-102. PubMed ID: 19254349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of JAK3, JAK2, and C-MPL mutations in transient myeloproliferative disorder and myeloid leukemia of Down syndrome blasts in children with Down syndrome.
    Norton A; Fisher C; Liu H; Wen Q; Mundschau G; Fuster JL; Hasle H; Zeller B; Webb DK; O'Marcaigh A; Sorrell A; Hilden J; Gamis A; Crispino JD; Vyas P
    Blood; 2007 Aug; 110(3):1077-9. PubMed ID: 17644747
    [No Abstract]   [Full Text] [Related]  

  • 8. MPL mutation profile in JAK2 mutation-negative patients with myeloproliferative disorders.
    Ma W; Zhang X; Wang X; Zhang Z; Yeh CH; Uyeji J; Albitar M
    Diagn Mol Pathol; 2011 Mar; 20(1):34-9. PubMed ID: 21326037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MassARRAY assay: a more accurate method for JAK2V617F mutation detection in Chinese patients with myeloproliferative disorders.
    Fu JF; Shi JY; Zhao WL; Li G; Pan Q; Li JM; Hu J; Shen ZX; Jin J; Chen FY; Chen SJ
    Leukemia; 2008 Mar; 22(3):660-3. PubMed ID: 17728780
    [No Abstract]   [Full Text] [Related]  

  • 10. Sensitive and accurate quantification of JAK2 V617F mutation in chronic myeloproliferative neoplasms by droplet digital PCR.
    Waterhouse M; Follo M; Pfeifer D; von Bubnoff N; Duyster J; Bertz H; Finke J
    Ann Hematol; 2016 Apr; 95(5):739-44. PubMed ID: 26931113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Establishment of a system for rapid detection of JAK2 V617F mutation in myeloproliferative diseases].
    Zhang Q; Zhang Y; Xu X; Zhou W; Fan X
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2019 Oct; 36(10):980-984. PubMed ID: 31598940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders.
    Jost E; do O N; Dahl E; Maintz CE; Jousten P; Habets L; Wilop S; Herman JG; Osieka R; Galm O
    Leukemia; 2007 Mar; 21(3):505-10. PubMed ID: 17230231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The quantitative evaluation of mutation V617F of gene JAK2 under chronic myeloproliferative diseases].
    Abdullaeva AO; Glinshchikova OA; Suslova SA; Shadieva NKh; Kolosova LIu; Meshcheriakova LM; Vakhrusheva MV; Sudarikov AB
    Klin Lab Diagn; 2012 Jul; (7):24-8. PubMed ID: 22988798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A quantitative assay for JAK2 mutation in 135 patients with chronic myeloproliferative neoplasms].
    Chao HY; Shen YM; Zhang R; Feng YF; Cen JN; Yao L; Shen HJ; Zhu ZL; Xue YQ
    Zhonghua Xue Ye Xue Za Zhi; 2009 May; 30(5):321-5. PubMed ID: 19799128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fully automated and super-rapid system for the detection of JAK2V617F mutation.
    Tanaka R; Kuroda J; Stevenson W; Ashihara E; Ishikawa T; Taki T; Kobayashi Y; Kamitsuji Y; Kawata E; Takeuchi M; Murotani Y; Yokota A; Hirai M; Majima S; Taniwaki M; Maekawa T; Kimura S
    Leuk Res; 2008 Sep; 32(9):1462-7. PubMed ID: 18328559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Referral centre variation in requesting JAK2 V617F mutation analysis for the investigation of a myeloproliferative neoplasm.
    Langabeer SE
    J Clin Pathol; 2012 Dec; 65(12):1149-50. PubMed ID: 22872706
    [No Abstract]   [Full Text] [Related]  

  • 18. Why do we see JAK2 exon 12 mutations in myeloproliferative neoplasms?
    Vorechovsky I; Jones AV; Cross NC
    Leukemia; 2013 Sep; 27(9):1930-2. PubMed ID: 23511126
    [No Abstract]   [Full Text] [Related]  

  • 19. A new MALDI-TOF-based assay for monitoring JAK2 V617F mutation level in patients undergoing allogeneic stem cell transplantation (allo SCT) for classic myeloproliferative disorders (MPD).
    Koren-Michowitz M; Shimoni A; Vivante A; Trakhtenbrot L; Rechavi G; Amariglio N; Loewenthal R; Nagler A; Cohen Y
    Leuk Res; 2008 Mar; 32(3):421-7. PubMed ID: 17698191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitation of JAK2 V617F Allele Burden by Using the QuantStudio™ 3D Digital PCR System.
    Kinz E; Muendlein A
    Methods Mol Biol; 2018; 1768():257-273. PubMed ID: 29717448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.